ECP 2023 Final Programme

Poster Sessions a Sunday 83 ECP 2023 Dublin Sunday, 10 Sept PS-01 015 HER2 assessment in breast cancer – routine diagnostics vs. segment-based annotations in multi-institutional raters Ramona Erber, Germany J. Steenpass, M. Öttl, C. Schmidt, M. Ruebner, P. Fasching, M. Beckmann, C. Taverna, F. Tava, C. Lang-Schwarz, A. Hartmann, K. Breininger 016 Residual lymphovascular invasion after neoadjuvant chemotherapy is associated with poor prognosis in breast carcinoma Gorana Gasljevic, Slovenia N. Pislar, A. Perhavec 017 Lack of deletion of 1p36 in primary adenoid cystic carcinoma of the breast Gorana Gasljevic, Slovenia B. Grcar-Kuzmanov, S. Borstnar, J. Contreras Bandres 019 Hypoxia and immune evasion in young women with breast cancer: a popula- tion-based study Rasmus Humlevik, Norway A. Svanøe, G. Knutsvik, A. Sæle, C. Askeland, L. Ingebriktsen, U. Hugaas, A. Kvamme, K. Krüger, B. Davidsen, T. Aas, I. Stefansson, E. Hoivik, L. Akslen, E. Wik 020 Assessment of PD-L1 expression in triple-negative breast carcinoma: the first north African case series Mouna Khmou, Morocco 021 A Canadian experience in proficiency testing for HER2-low breast cancers Zuzana Kos, Canada J. Garratt, J. Won, B. Sheffield, B. Gilks 022 MHC class I and PD-L1 expression in ductal carcinoma in situ subtypes of the breast: impact on T-cell infiltration and clinical outcome Ji Shin Lee, Korea M. Park, N. Kim 023 Impact of HER2 assay sensitivity on the ability to detect tumours with low to ultra-low HER2 expression: a TMA study on more than 10,000 tumours from more than 100 tumour entities Maximilian Lennartz, Germany N. Blessin, D. Dum, D. Hoeflmayer, S. Weidemann, G. Sauter, T. Clauditz, F. Jacobsen, T. Krech, A. Marx, S. Minner, R. Simon, N. Gorbokon, S. Steurer, E. Burandt 024 Discordance in molecular (Prosigna ®) and surrogate (immunohistochemistry) subtyping of breast carcinoma Gustavo Adolfo Martín Small, Spain A. Castillo, L. Pons, C. Perelló-Fabregat, P. Rodríguez-Martínez, E. Castellà, A. Muñoz-Mármol, A. Urbizu, L. Arnaldo, M. Martín-Céspedes, R. Marginet-Flinch, M. Jimeno, M. Margelí, C. Sanz, P. Fernández 025 Atlas of ex vivo breast tissue and carcino- mas images by ultra-fast large field-of-view fluorescence confocal microscopy of lumpectomy Marie-Christine Mathieu, France M. Ragazzi, P. Van Diest, M. Ferchiou, O. Casiraghi, N. Labaied, A. Conversano, M. Abbaci 026 Association of serum inflammatory profiles with breast cancer immunophenotypes and clinicopathological factors Yoel Genaro Montoyo Pujol, Spain S. Pascual-García, P. Martínez-Peinado, A. López-Jaén, J. Ponce, I. Lozano, T. Martín- Bayón, H. Ballester, A. Ramos, S. Delgado, E. Castellón-Mollá, J. Sempere-Ortells, G. Peiró 027 HER2-Low breast cancer: incidence and observer variability Fátima Ramalhosa, Portugal G. Fontinha, S. Bárbara, C. Faria, R. Celestino, M. Cipriano, M. Martins 028 Clinicopathological spectrum of adenomy- oepithelioma: a tertiary care cancer center experience of a rare entity Ayushi Sahay, India M. Aziz, A. Patil, T. Shet, S. Desai